AOD-9604 is a synthetic 16-amino-acid peptide corresponding to the C-terminal fragment of human growth hormone, residues 176–191, with an additional tyrosine residue added at the N-terminus. AminoOptimization Group supplies it as a lyophilised research powder in a 5 mg presentation, tested to 99% purity by HPLC, with a Certificate of Analysis available for the lot supplied. This material is offered strictly for laboratory research use. It is not a drug, and it is not for human or veterinary use.
What is AOD-9604?
AOD-9604, also referenced in the literature as Tyr-hGH Fragment 176-191, is derived by truncating the 191-amino-acid human growth hormone sequence down to its C-terminal segment and appending a tyrosine residue at the free N-terminus, a modification originally introduced to permit radiolabelling in early receptor-binding assays. The truncation removes the regions of the hGH molecule responsible for binding the principal signalling site on the growth hormone receptor — the interaction associated with longitudinal growth and with GH’s characteristic effect on insulin sensitivity.
What remains is the segment of hGH identified in structure-function work as its “lipolytic domain,” a short C-terminal sequence studied for activity in adipocyte lipid metabolism reported to be independent of the canonical JAK2/STAT5 pathway that mediates most of the parent hormone’s other actions. This structural separation is the basis for treating AOD-9604 as a distinct research entity rather than simply a shortened growth hormone: published work describes it as pharmacologically dissociated from the GH receptor’s growth-promoting signalling. It is also mechanistically distinct from GHRH analogues such as CJC-1295 and ghrelin-receptor secretagogues such as ipamorelin, both of which act upstream to stimulate endogenous GH release; AOD-9604 is itself an hGH-derived fragment, studied for a proposed downstream activity attributed to the hormone’s C-terminus rather than for any effect on pituitary GH secretion.
Specifications
- Compound: AOD-9604 / Tyr-hGH Fragment 176-191
- CAS number: 221231-10-3
- Molecular formula: C78H123N23O23S2
- Molecular weight: 1815.1 g/mol
- Purity: 99% HPLC
- Presentation: Lyophilised powder, sealed vial
- Available sizes: 5 mg
- Physical form: White to off-white powder
- Classification: Research peptide — not for human or veterinary use
Research context
Published research on AOD-9604 focuses on its interaction with adipocyte lipid metabolism in isolated-cell and rodent model systems, examining lipolysis — the breakdown of stored triglyceride — and the inhibition of lipogenesis, the synthesis of new fat. Because the fragment lacks the domains needed for classical GH receptor activation, this line of research has proposed alternative signalling routes, including interaction with beta-3 adrenergic receptors on the adipocyte membrane, as the mechanism under investigation rather than the GH receptor pathway itself.
AOD-9604 also has a documented clinical trial history. It was examined in registered Phase I through Phase III trials sponsored by an Australian biotechnology group studying body-composition endpoints in adult subjects with obesity, a programme that was discontinued after a Phase IIb trial reported in the literature failed to separate from placebo on its primary endpoint. That trial record forms part of the published literature on the compound and is noted here for that reason. None of this literature establishes safety or efficacy for use in humans. It is provided as research context only.
Reconstitution
Lyophilised peptide requires reconstitution with a suitable sterile diluent before use in solution. Bacteriostatic water is the diluent most commonly specified for multi-use laboratory preparations; sterile water is typical for single-use work.
Direct the diluent stream against the inner wall of the vial rather than onto the powder itself, and allow the material to dissolve without agitation. Peptides are susceptible to shear stress — do not shake the vial. Swirl gently if needed, and expect full dissolution within a few minutes at room temperature.
Working concentration is a function of how much diluent is added to a given vial mass. Our peptide reconstitution calculator computes the resulting concentration for any combination of vial size and diluent volume.
Storage and stability
Before reconstitution: store the sealed vial in a freezer at -20 °C, protected from light. Lyophilised peptide is comparatively stable in this state. Brief excursions to ambient temperature during shipping are normal and are not expected to compromise a properly lyophilised product.
After reconstitution: refrigerate at 2–8 °C and protect from light. Reconstituted peptide in solution is materially less stable than the dry powder. Avoid repeated freeze-thaw cycles, a well-documented cause of aggregation and loss of measurable potency — aliquot instead if repeated sampling is required.
Inspect solutions before use. Cloudiness, visible particulate, or discolouration indicate the material should not be relied upon for quantitative work.
Certificate of Analysis
Every lot is tested by high-performance liquid chromatography, and the purity figure shown above refers to analytical results for the specific lot supplied — not to a generic specification. A Certificate of Analysis is available on request, and we will provide lot-specific documentation before purchase if your protocol requires it.
Purity by HPLC describes the proportion of the target peptide relative to detectable related substances. It is a statement about the material as manufactured and tested. It is expressly not a representation that the material is suitable for any use in humans or animals.
Handling and safety
Handle in accordance with good laboratory practice. Use appropriate personal protective equipment, work in a suitable containment environment, and dispose of material and consumables according to your institution’s requirements and applicable local regulation. Anyone with access to this material should understand that it is not for human or veterinary use.
Frequently asked questions
What is the difference between AOD-9604 and full-length human growth hormone?
AOD-9604 is a 16-amino-acid fragment corresponding only to the C-terminal end of the 191-amino-acid hGH sequence. It lacks the regions of the full hormone that bind the growth hormone receptor’s principal signalling site, which published work links to GH’s effects on growth and insulin sensitivity.
Is AOD-9604 approved in Canada?
No. This compound has not been evaluated or authorised by Health Canada, the FDA, or any comparable regulatory authority. It carries no DIN or NPN, its safety and efficacy for human use have not been assessed, and it is supplied for laboratory research only.
How much diluent should be used to reconstitute AOD-9604?
That depends on the working concentration your protocol requires. Use the reconstitution calculator to work out the resulting concentration for a 5 mg vial.
How stable is AOD-9604 once reconstituted?
Stability in solution is shorter than in lyophilised form and depends on diluent, temperature, and handling. Refrigerate at 2–8 °C, protect from light, avoid freeze-thaw cycling, and validate stability for your own storage conditions if your work depends on it.
Do you provide a Certificate of Analysis for AOD-9604?
Yes — lot-specific, available on request, including before purchase.
Research use only
This product is supplied solely for laboratory and scientific research. It is not a drug, food, cosmetic, or medical device, and it must not be administered to humans or animals. Nothing on this page is medical advice or a therapeutic claim. Full terms are set out in our Research Use Only Disclaimer.
Reviews
There are no reviews yet.